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Summary
Background The economic burden on households affected by tuberculosis through costs to patients can be 
catastrophic. WHO’s End TB Strategy recognises and aims to eliminate these potentially devastating economic 
effects. We assessed whether aggressive expansion of tuberculosis services might reduce catastrophic costs.
Methods We estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of 
tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. Using modelled 
incidence and mortality for tuberculosis and patient-incurred cost estimates, we investigated three intervention 
scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; 
and expansion of access to tuberculosis care through intensified case finding (South Africa only). We defined 
tuberculosis-related catastrophic costs as the sum of direct medical, direct non-medical, and indirect costs to patients 
exceeding 20% of total annual household income. Intervention effects were quantified as changes in the number of 
households incurring catastrophic costs and were assessed by quintiles of household income.
Findings In India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant 
tuberculosis could reduce the number of households incurring tuberculosis-related catastrophic costs by 6–19%. 
The benefits would be greatest for the poorest households. In South Africa, expanded access to care could decrease 
household tuberculosis-related catastrophic costs by 5–20%, but gains would be seen largely after 5–10 years.
Interpretation Aggressive expansion of tuberculosis services in India and South Africa could lessen, although not 
eliminate, the catastrophic financial burden on affected households.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In May, 2014, the World Health Assembly ratified the 
End TB Strategy, which set aspirational worldwide 
objectives for tuberculosis control: reductions of 50% in 
global tuberculosis incidence and 75% in tuberculosis 
mortality by 2025, and of 90% and 95%, respectively, by 
2035.1 National policy makers are now deciding which 
interventions to implement to achieve these targets. The 
TB Modelling and Analysis Consortium assessed in 
its TB Targets exercise2 how expanding control by an 
ambitious but feasible degree might affect the targets 
being achieved in China, India, and South Africa.
In China, sustained improvements in tuberculosis 
interventions led to a 70% decline in prevalence from 
1990 to 2010,3,4 and by 2015, tuberculosis incidence had 
reached 70 cases per 100 000 population.3 By contrast, in 
South Africa, where the tuberculosis epidemic has been 
greatly affected by HIV dynamics,5,6 declines in 
tuberculosis incidence have been seen since only around 
2010, and in 2015 incidence was 830 cases per 100 000.3 
India has had relatively stable incidence of 200–300 cases 
per 100 000 population for the past 15 years, but faces 
challenges associated with a large and heterogeneous 
private sector that is used by many patients for diagnosis 
and care. By expanding government subsidies, India has 
attempted to improve the quality of tuberculosis care 
provided in the private sector.7
The TB Targets exercise was a modelling study done 
to assess the hypothetical effects of specific TB 
interventions and showed that the 2025 targets of the 
End TB Strategy would not be achieved by implementing 
any one intervention.2 In India and China, targets might 
only be met with aggressive implementation of a 
comprehensive set of currently available interventions 
and if new and improved technologies become 
available.2 Improvements need to be made in access to 
high-quality tuberculosis care, diagnosis, multidrug 
resistance (eg, by replacing smear microscopy with 
molecular diagnostic techniques), adherence and 
treatment success rates, active case finding in the 
general population, and use of isoniazid preventive 
therapy for people taking anti retroviral therapy.2 A 
concurrent economic evaluation found that such 
expansion was likely to be cost-effective and would avert 
large numbers of deaths per incremental tuberculosis 
budget dollar, but might need substantial increases in 
funding at the time of implementation,8 which in India 
and South Africa, would lead to annual tuberculosis 
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service costs more than doubling and rising to 3–4% of 
current public health financing.
The TB Targets exercise suggested that expanding 
tuberculosis control would substantially reduce costs 
incurred by patients8 and thereby also diminish 
tuberculosis-related household impoverishment. This 
outcome would be important given the WHO’s aim of 
universal health coverage and the fact that out-of-pocket 
medical costs are a leading cause of impoverishment in 
many low-income and middle-income countries.9 Survey 
evidence also suggests that in such settings tuberculosis 
leads to substantial losses in wages and work productivity 
for the affected individuals and their households.10
One of the three goals of the End TB Strategy is that no 
patient or their household should face catastrophic costs 
because of tuberculosis.11,12 This goal is consistent with 
WHO having made protection from financial risks and 
prevention of medical impoverishment key elements of 
health-system performance13 and included financial 
protection in universal health coverage.14 Given the 
association between tuberculosis and poverty, and the 
recommendation to monitor related catastrophic costs,11,12 
it is essential to understand how different interventions 
might prevent impoverishment. Traditional cost-
effectiveness analysis may be complemented by extended 
cost-effectiveness analysis (ECEA), which estimates the 
distributional and financial protection benefits to be 
gained by resource allocation15,16 and, hence, when com-
bined with modeling, can explore the financial protection 
impact of different tuberculosis interventions.
We developed a mathematical model to assess whether 
tuberculosis-related household catastrophic costs could be 
reduced by expansion of tuberculosis interventions in 
India and South Africa, building on the TB Targets 
exercise2,8 and consistent with ECEA. We compared a 
subset of interventions highlighted by the TB Targets 
exercise with a base case derived from the standards of 
tuberculosis care in these countries at the start of the study. 
Methods
Study design
We did a modelling study to assess effects of different 
interventions on catastrophic costs related to tuberculosis 
in the period 2016–35. We selected India and South 
Africa for this study because they are both major con-
tributors to the global tuberculosis burden but differ in 
HIV and tuberculosis epidemiology, approaches to 
tuberculosis control, mix of public and private health-
care provisions, and the availability of data on costs 
incurred by patients; although the main TB Targets 
analysis also included China, we only selected India and 
South Africa because of the criteria specified. India has 
the largest national tuberculosis burden worldwide and a 
large private sector providing care to about half of 
affected individuals.17 South Africa has the largest 
tuberculosis burden per person worldwide, and HIV and 
tuberculosis are closely linked in this country.6
Intervention scenarios
In each country, we consulted extensively with 
representatives from national tuberculosis programmes 
to decide on the activities that would be most relevant to 
assess with existing tools. We selected interventions with 
clear information on implementation and coverage, and 
with detailed future scenarios based on a framework of 
tuberculosis programme activities (table 1, appendix p 2). 
Research in context
Evidence before this study
WHO’s End TB Strategy proposes aggressive action to reduce 
tuberculosis incidence and mortality. Associated with those 
goals will be reductions in related out-of-pocket costs and 
impoverishment, which can be catastrophic when they place 
excessive economic burden on households. Although the 
economic burden of tuberculosis on households is known to be 
high, there is little evidence reported on the effects of financial-
risk protection strategies in high-burden settings, such as India 
and South Africa. The TB Modelling and Analysis Consortium 
highlighted two reports on the End TB Strategy which 
suggested through estimation of costs incurred by patients in 
high-burden settings that substantial improvements in 
tuberculosis control could be cost-effective.
Added value of this study
We used models to estimate reductions in tuberculosis-related 
catastrophic costs with aggressive expansion of tuberculosis 
services in India and South Africa from 2016 to 2035. 
We quantified intervention effects as changes in the number of 
households incurring catastrophic costs, which were defined as 
the sum of direct medical and non-medical costs and indirect 
costs being more than 20% of the total household income. 
We estimated that improved care for drug-sensitive and 
multidrug-resistant tuberculosis would lead to reductions of up 
to 19% in India and South Africa, and found that benefits would 
be greatest in the poorest households. In South Africa, the 
expansion of access to care through intensified case finding 
could decrease tuberculosis-related household catastrophic 
costs by up to 20%. 
Implications of all the available evidence
Aggressive expansion of tuberculosis services in India and 
South Africa could alleviate the financial burden on many 
patients. Nevertheless, improved social protection for people 
with tuberculosis will still be needed to meet the End TB 
Strategy target of eliminating catastrophic costs. Our results 
support efforts to scale up tuberculosis services and moving 
towards universal health coverage. 
See Online for appendix
Articles
www.thelancet.com/lancetgh   Vol 5   November 2017 e1125
We assessed the effects of improvement in treatment 
quality for drug-sensitive and multidrug-resistant 
tuberculosis in South Africa and India. In India, there 
are many treatment providers of widely varying 
qualities,17–19 and, therefore, the treatment interventions 
allowed exploration of achievements if increased 
proportions of individuals with tuberculosis could access 
higher-quality care in this country (similar to optimum 
public sector care). We also assessed expansion of access 
to care through intensified tuberculosis screening at 
primary-care clinics in South Africa. In the intervention 
scenarios, high coverage was reached by 2025 and 
remained constant for 10 years over 2025–35. The 
models also considered local policy constraints and 
system capacities.2,8
In India, we took improvement in quality of treatment to 
mean that treatment adherence would increase from 75% 
to 85% for drug-sensitive tuberculosis and from 48% to 
67% for multidrug-resistant tuberculosis. These changes 
would be achieved in both intervention scenarios through 
improved quality of private-sector treatment by provider 
training, supervision, regulation, and subsidies, and 
provision of patient-retention incentives, nutritional 
support, and linkage to social welfare programmes. In 
South Africa, we took improvement in quality of treatment 
to mean that treatment adherence would increase from 
76% to 85% for drug-sensitive tuberculosis and from 52% 
to 67% for multidrug-resistant tuberculosis. These changes 
would be achieved in both intervention scenarios through 
provision of mobile health care and follow-up in the 
community, offering patients adherence counselling and 
psychosocial support, and tracing of patients to avert 
care dropout. Additional features to achieve improved 
treatment of multidrug-resistant tuberculosis would be 
increased staffing and decentralisation of the electronic 
register. We took expansion of access to care in South Africa 
to mean that all individuals seeking care would be screened 
for symptoms of tuberculosis.
We compared each intervention scenario with a base 
case, which assumed that coverage and treatment success 
rates at the start of the study would be maintained at a 
constant for the period 2016–35. The baseline trends in 
tuberculosis incidence and mortality projected in the base 
case were inferred from model calibration with 2012 
survey data and past trends from 2000–15.2 The base case 
included country standards of care derived from the FIND 
study in India20 and the XTEND study in South Africa.21,22
Calculation of catastrophic costs
We defined catastrophic costs as the sum of direct 
medical costs (eg, treatment costs), direct non-medical 
costs (eg, transport and food during visits), and indirect 
costs (eg, loss of earnings) to the patient exceeding 20% 
of total annual household income.23.24 This definition 
followed that in WHO’s protocol to estimate the 
proportion of households experiencing tuberculosis-
related catastrophic costs.24 A simplifying assumption 
was made that each household could have a maximum 
of one case of tuberculosis.
We calculated household catastrophic costs for each 
intervention scenario and the base case. Indirect costs 
were estimated for the time before diagnosis of 
tuberculosis when patients were not taking treatment 
and, therefore, reductions due to interventions were 
quantified as estimated reductions in the time from 
onset of tuberculosis symptoms to diagnosis (table 2).
Modelling
Modelling involved four steps for each country. Step 1 
involved collecting the number of tuberculosis cases and 
deaths for each intervention and year. In line with the TB 
Targets exercise, we used two dynamic deterministic 
compartmental models of tuberculosis transmission, the 
Harvard model developed by Menzies and colleagues35 
and the model of the TB Impact Model and Estimates 
group (appendix p 1).36 Both models use the following 
Activities Programme targets Mechanism of action for 
health effects
India
Improving 
treatment 
quality
Improved private-sector quality through 
provider training, supervision, regulation, 
and subsidies; retention of patients in care 
by incentives, nutritional support, and link 
to social welfare programmes
Initial decrease in patients stopping treatment from 10% to 
5% by 2015 for DS-TB and from 11% to 5% by 2020 for MDR-
TB; treatment success measured as increases in adherence 
from 75% to 85% and from 48% to 67%, respectively
Improved retention of patients 
receiving care leading to 
increased cure rates 
South Africa
Expanding 
access to care
Outreach clinics to underserved areas and 
symptom screening in primary care
Decrease population without access to care from 5% to zero 
by 2022
Reduced duration of 
infectiousness and mortality 
risks by improved case detection
Improving 
treatment 
quality
Mobile health care, follow-up of patients in 
the community, counselling on adherence to 
treatment, and improved MDR-TB staffing
Initial decreases in patients stopping treatment from 17% to 5% 
by 2021 for DS-TB and from 30% to 15% by 2021 for MDR-TB; 
treatment success measured as increases in adherence from 
76% to 85% and from 52% to 67%, respectively
Improved retention of patients 
receiving care leading to 
increased cure rates
DS-TB=drug-sensitive tuberculosis. MDR-TB=multidrug-resistant tuberculosis. 
Table 1: Intervention scenarios for India and South Africa8
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factors to stratify populations: drug-sensitive or 
multidrug-resistant tuberculosis, treatment history for 
tuberculosis, HIV status, receiving antiretroviral therapy, 
and CD4 cell count. The Harvard model followed one age 
group (>15 years) and used Bayesian calibration, whereas 
the TB Impact Model and Estimates model tracked the 
whole population and used manual calibration.2 We used 
the following model outputs to estimate patient-incurred 
costs throughout the period 2016–35: the number of 
tuberculosis cases screened and diagnosed; the numbers 
of patients with tuberculosis who received treatment for 
drug-sensitive tuberculosis or for multidrug-resistant 
tuberculosis; time from onset of tuberculosis symptoms 
to starting treatment; and the number of tuberculosis-
related deaths (table 2). The estimated numbers of 
tuberculosis cases screened, diagnosed, and treated for 
drug-sensitive or multidrug-resistant tuberculosis, as 
estimated by the models for the base case and the 
intervention scenarios, were distributed across income 
quintiles by an income distribution analysis. Data for 
tuberculosis prevalence25,26 and health-care use27,28 were 
obtained from the literature. We used case-fatality ratios 
to allocate tuberculosis-related deaths between people 
who were treated and those who remained untreated.37
In step 2, we used the estimates of direct and indirect 
costs incurred by patients (table 2), which were based on 
an analysis of surveys by Menzies and colleagues 
(appendix pp 3–7),8 to assess the effects of each intervention. 
These estimates provided the unit cost per model output 
from the patient’s perspective and estimated a mean cost 
per tuberculosis-affected household. Indirect costs 
compared with average income were varied by income 
quintile (–20%, –10%, 0, 10%, 20% in quintiles 1 to 5, 
respectively), and we included costs for tuberculosis-
related deaths (eg, funeral costs32,33).
In step 3, we assigned an annual income for each 
tuberculosis-affected household, based on the income 
distribution defined for each tuberculosis case in step 1, 
drawn from a simulated γ distribution with parameters 
based on the country’s gross domestic product per capita 
and Gini index (table 2).34,38,39 We then determined the 
size of each household with a Poisson model, with the 
average size taken from each country’s national census 
(four per household in South Africa and five in India).40,41 
This approach allowed us to define household annual 
income in each quintile (table 2) and thus to which 
income quintile each case of tuberculosis should be 
assigned.
In step 4, we calculated the number of households 
incurring catastrophic costs per year and cumulatively in 
2016–35, by income quintile. We combined the estimated 
household income for each quintile with the patient-
incurred costs estimated in step 2 (table 2). To obtain the 
total number of cases of catastrophic costs averted by 
each intervention scenario, we subtracted the number of 
households incurring catastrophic costs in the base 
case from the number in the intervention scenario 
(appendix pp 8–9).
Further sensitivity and scenario analyses
We did three univariate sensitivity analyses to assess the 
effects of key factors, varying the following factors by 50% 
above and below baseline values: direct costs, funeral costs, 
and health-care use (appendix pp 24–35). Furthermore, we 
ran a probabilistic sensitivity analysis with Monte Carlo 
simulations (n=100 000 trials), where time to diagnosis, 
health-care use, income, and costs to patients were varied 
simultaneously with truncated normal distributions, with 
input means extracted from the model outputs and 20% of 
those means used to calculate SDs. From these data we 
India South Africa References
Epidemiology
Cumulative numbers (2016–35) in base case in Harvard model and TIME model
Treated DS-TB cases 49 785 000, 32 877 000 6 211 000, 5 342 000 2
Treated MDR-TB cases 851 000, 1 258 000 160 000, 318 000 2
Tuberculosis-related deaths 6 547 000, 8 210 000 1 316 000, 1 345 000 2
Estimated relative risk of tuberculosis, 
from poorest to richest quintile
1·00, 0·66, 0·50,  
0·28, 0·18
1·00, 0·66, 0·57, 
0·47, 0·17
25, 26
Estimated relative ratio of health-care 
use, from poorest to richest quintile
0·18, 0·39, 
0·59, 0·80, 1·00
0·67, 0·75, 
0·83, 0·92, 1·00 
27, 28
Direct medical costs to patients
Monthly costs (US$)
DS-TB care (base case) 61 38 8, 10, 29, 30
MDR-TB care (base case) 61 123 8, 29–31
Improved DS-TB care 48 38 8, 10, 29,30
Improved MDR-TB care 48 123 8, 29–31
Fixed costs (per visit)* 42 N/A 8, 10, 29, 30
Direct non-medical and indirect costs to patients
Average time from onset to diagnosis 
in base case in Harvard model and 
TIME model (months)
11·9, 20·4 9·7, 9·9 2
Average time from onset to diagnosis 
with expansion of access to care in 
Harvard model and TIME model 
(months)
N/A 6·6, 6·9 2
Diagnosis cost per month ($)† 60 66 8, 10, 29, 30
Funeral costs ($) 300 1850 32, 33
Annual income per capita ($) 1600 6890 34
Gini index‡ 0·33 0·65 34
Distribution of annual income per capita by income quintile ($)
1 <750 <2760 ··
2 750–1170 2760–4530 ··
3 1170–1640 4530–6580 ··
4 1640–2320 6580–9630 ··
5 >2320 >9630 ··
DS-TB care implies 6 months of treatment and MDR-TB care implies 24 months of treatment. In the base case, 
all coverage levels and treatment success rates at the start of the study were assumed to be maintained at a 
constant for the period 2016–35. Costs are expressed in 2014 US$. TIME=TB Impact Model and Estimates. 
DS-TB=drug-sensitive tuberculosis. MDR-TB=multidrug-resistant tuberculosis. N/A=not applicable. *Include 
per-visit costs to physicians for diagnosis of tuberculosis. †Includes indirect social care and transport costs per 
month until tuberculosis is diagnosed. Reduction in indirect cost is then valued through the reduction of time to 
tuberculosis diagnosis after onset of interventions. ‡Measure of inequality of income distribution. 
Table 2: Parameters used to estimate catastrophic costs averted 
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extrapolated 2·5 and 97·5 percentiles to determine 
95% uncertainty ranges.
We did four scenario analyses. First, we varied the 
burden distribution and assumed that tuberculosis 
cases were equally distributed across income quintiles 
(ie, removing the assumption that tuberculosis would 
occur more in the poor). Second, we varied the distribution 
of health-care use and assumed equal access to care across 
each quintile (ie, removing the assumption that the richer 
patients would seek care more than the poorer patients). 
Third, we modified the patient-incurred costs by removing 
costs arising from tuberculosis-related deaths and 
assuming equal indirect costs across quintiles. Fourth, we 
changed the catastrophic costs metric by changing the 
threshold from 20% to 10% or 40% of total household 
income42–44 or by using a different threshold for each 
quintile (eg, 20%, 25%, 30%, 35%, and 40%). All costs 
were expressed in 2014 US$. All analyses were done with 
RStudio (version 1.0.136).
Role of the funding source
The funder had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
The estimated numbers of households that incurred 
tuberculosis-related catastrophic costs in 2016–35, were 
around 20 million to 22 million in India and 1·1 million 
to 1·2 million in South Africa (tables 3, 4). We found a 
Total number of 
households (95% UR)
Number of households (95% UR) per income quintile*
1 2 3 4 5
Harvard model
Base case 20 596 (16 848–24 278) 8785 (8276–9203) 5955 (4334–7394) 4199 (3024–5449) 1332 (920–1874) 326 (197–512)
Improvement in 
DS-TB care
19 544 (15 976–23 049) 8357 (7864–8766) 5638 (4104–7006) 3979 (2864–5168) 1261 (871–1775) 309 (187–486)
Improvement in 
MDR-TB care
20 475 (16 753–24 130) 8739 (8232–9155) 5917 (4309–7349) 4171 (3005–5413) 1324 (915–1860) 324 (196–509)
TIME model
Base case 21 926 (18 864–24 629) 6757 (6442–7106) 7101 (6370–7571) 5383 (3854–6685) 2036 (1425–2740) 649 (493–826)
Improvement in 
DS-TB care
20 547 (17 690–23 079) 6381 (6065–6732) 6635 (5950–7074) 5027 (3602–6243) 1898 (1329–2556) 605 (459–771)
Improvement in 
MDR-TB care
21 790 (18 742–24 485) 6696 (6378–7049) 7059 (6327–7526) 5360 (3839–6659) 2028 (1419–2731) 647 (491–824)
Catastrophic costs are defined as the sum of costs exceeding 20% of total household income. In the base case, all coverage levels and treatment success rates at the start of 
the study were assumed to be maintained at a constant for the period 2016–35. UR=uncertainty range. DS-TB=drug-sensitive tuberculosis. MDR-TB=multidrug-resistant 
tuberculosis. TIME=TB Impact Model and Estimates. *From poorest (quintile 1) to richest (quintile 5).  
Table 3: Estimated numbers of households (in thousands) incurring tuberculosis-related catastrophic costs in India
Total number of 
households (95% UR)
Number of households (95% UR) per income quintile*
1 2 3 4 5
Harvard model
Base case 1184 (1031–1348) 925 (805–1049) 195 (163–231) 59 (42–78) 5 (0–11) 0 (0–2)
Expansion of access to care 1123 (972–1279) 882 (769–999) 199 (165–235) 38 (22–57) 3 (0–7) 0 (0–2)
Improvement in DS-TB care 964 (836–1103) 757 (657–861) 158 (129–190) 45 (30–61) 4 (0–9) 0 (0–2)
Improvement in MDR-TB care 965 (837–1105) 759 (658–865) 157 (129–190) 44 (30–60) 4 (0–9) 0 (0–2)
TIME model
Base case 1243 (1085–1396) 984 (864–1096) 172 (141–205) 81 (58–103) 7 (1–14) 0 (0–1)
Expansion of access to care 999 (874–1130) 802 (709–898) 143 (113–173) 49 (33–68) 5 (0–12) 0 (0–1)
Improvement in DS-TB care 1152 (1005–1297) 915 (803–1021) 159 (129–190) 72 (52–93) 6 (0–14) 0 (0–1)
Improvement in MDR-TB care 1171 (1016–1320) 934 (816–1044) 157 (127–189) 73 (52–94) 6 (0–14) 0 (0–1)
Catastrophic costs are defined as the sum of costs exceeding 20% of total household income. In the base case, all coverage levels and treatment success rates at the start of 
the study were assumed to be maintained at a constant for the period 2016–35. UR=uncertainty range. DS-TB=drug-sensitive tuberculosis. MDR-TB=multidrug-resistant 
tuberculosis. TIME=TB Impact Model and Estimates. *From poorest (quintile 1) to richest (quintile 5). 
Table 4: Estimated number of households (in thousands) incurring tuberculosis-related catastrophic costs in South Africa 
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substantially higher risk of catastrophic costs being 
incurred in the bottom 40% of households in each 
country, among which the prevalence of tuberculosis was 
highest. In India, 30–40% of all catastrophic costs were 
estimated to be in the bottom income quintile, and in 
South Africa the proportion was about 80%.
In India, more catastrophic costs would be averted by 
improvements in drug-sensitive tuberculosis care than 
by improvements in multidrug-resistant tuberculosis 
care (figure 1), and the difference between these two 
interventions would increase over time (figure 2). Over 
2016–35, improvements in care for drug-sensitive 
tuberculosis would avert about 1·1 million to 1·4 million 
cases of household catastrophic costs (table 3), which was 
about 5–6% of all cases in the base case. Improvements 
in care of multidrug-resistant tuberculosis would avert 
about 120 000–140 000 cases or up to 1% of all cases 
incurred in the base case (table 3). These cost reductions 
would occur because of the provision of financial 
incentives to patients in the intervention and the 
prevention of additional tuberculosis transmission and 
infections.2,8 The benefits of these two interventions 
would be greatest in the lowest two income quintiles 
(poorest 40% of households), where 60–70% of cases of 
catastrophic costs would be averted by improvements in 
care of drug-sensitive tuberculosis and 70–80% would be 
averted by improvements in care for multidrug-resistant 
tuberculosis. These reductions would be due to 
decreasing tuberculosis incidence, increasing health-care 
use, and decreasing likelihood of catastrophic costs with 
increasing income.
In South Africa, the numbers of cases of tuberculosis-
related household catastrophic costs averted by 
improvements in care of drug-sensitive and multidrug 
resistant tuberculosis would be lower than in India 
(figures 3, 4). Expanding access to care through intensified 
case finding would avert about 60 000–240 000 cases of 
catastrophic costs in 2016–35 (table 4), which was about 
5–20% of all cases incurred in the base case, although 
effects would not be seen for around 5–10 years (figure 4). 
With improvements in care of drug-sensitive tuberculosis, 
about 90 000–220 000 cases or 7–19% of all cases of 
catastrophic costs would be averted, as would 
70 000–220 000 cases or 6–18% with improvements in care 
Figure 1: Number of households in India with catastrophic costs averted by 
improved tuberculosis care, compared with the base case, by income quintile
(A) Harvard model. (B) TB Impact Model and Estimates model. The base case 
covers the period 2016–35, during which all coverage levels and treatment 
success rates were assumed to be maintained at a constant. Numbers of 
households are shown with 95% uncertainty ranges. Quintiles range from 
poorest (quintile 1) to richest households (quintile 5). DS-TB=drug-sensitive 
tuberculosis. MDR-TB=multidrug-resistant tuberculosis.
Figure 2: Number of households in India per year with catastrophic costs 
averted by improved tuberculosis care over the period 2016–35
(A) Harvard model. (B) TB Impact Model and Estimates model. DS-TB=drug-
sensitive tuberculosis. MDR-TB=multidrug-resistant tuberculosis.
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of multidrug-resistant tuberculosis (table 4). Households 
in the lowest two income quintiles would benefit the most 
from all three interventions. Expanded access to care 
would avert 65–90% of tuberculosis-related catastrophic 
costs in these quintiles, and improvements in care of 
drug-sensitive tuberculosis and multidrug-resistant 
tuberculosis, would each avert about 90% of cases.
In the sensitivity analysis, assigning uniform 
distribution of tuberculosis lessened the difference in 
effects between quintiles (appendix pp 10–11). With equal 
use of health care across quintiles, in India and South 
Africa, reductions remained highest in the bottom 
income quintile (appendix pp 12–13). Removing funeral 
costs due to tuberculosis-related deaths had little effect 
on the number of cases of catastrophic costs averted in 
any quintile with improvements in care of drug-sensitive 
and multidrug-resistant tuberculosis in both countries 
(appendix pp 14–15). Uniform distribution of indirect 
costs across quintiles led to reductions in catastrophic 
costs in the higher quintiles and increases in the lower 
quintiles (appendix pp 16–17). When we varied the 
threshold for estimating catastrophic costs to 10% or 
40%, or used varying thresholds by quintile, the numbers 
of cases of catastrophic costs increased with the lower 
thresholds and decreased with the upper thresholds 
(appendix pp 18–23).
Discussion
We developed an approach to assess the financial 
protection benefits of tuberculosis control in terms of 
cases of tuberculosis-related household catastrophic 
costs averted if selected interventions were implemented 
in India and South Africa from 2016–35. Without 
intervention, our base case indicated that tuberculosis-
related household catastrophic costs would remain 
substantial in India and South Africa. Improvements in 
the quality of care for drug-sensitive and multidrug-
resistant tuberculosis could reduce this financial burden, 
but even with aggressive efforts, the End TB Strategy 
target of no households facing tuberculosis-related 
catastrophic costs by 2030 would be far from being 
achieved in either country.
In the base case, the two lowest income quintiles bore 
most of the catastrophic costs, which is consistent with 
findings from other studies, for example in Nigeria45,46 
and Peru.23 We note, though, that although the gains in 
financial protection would be greatest in these two 
quintiles, the reductions would be less than 20%. Other 
policy actions, therefore, will be needed to reduce 
tuberculosis incidence and mortality. In India, the 
interventions included some payments to patients with 
tuberculosis to lessen the direct costs of accessing care, 
but these were not sufficiently large to combat the high 
indirect costs incurred. Tuberculosis is a debilitating 
illness that lasts long enough to adversely affect earning 
potential and, therefore, additional support is needed to 
alleviate these costs if households are to be protected. 
Based on a framework of tuberculosis programme 
activities and extensive discussions with national 
tuberculosis programme representatives, we studied the 
interventions of improved care for drug-sensitive and 
multidrug-resistant tuberculosis and expanded access to 
care through intensified case finding. Assessment of 
other interventions, such as expanding existing national 
social protection schemes for the poorest households 
and vulnerable populations, however, would be worth-
while, as has been proposed by WHO and partners of the 
newly established Health and Social Protection Action 
Research and Knowledge Sharing Network.47 The inter-
ventions we studied were focused on the delivery of core 
tuberculosis services, but in the future we might consider 
assessing systemic interventions that could reduce 
financial costs, such as decentralised care, fees, and 
transport support. Intervention coverage is only one 
element among many, including quality and financial 
Figure 3: Number of households in South Africa with catastrophic costs 
averted by intensified case finding and improved tuberculosis care, 
compared with the base case, by income quintile
(A) Harvard model. (B) TB Impact Model and Estimates model. The base case 
covers the period 2016–35, during which all coverage levels and treatment 
success rates were assumed to remain at a constant. Numbers of households are 
shown with 95% uncertainty ranges. Quintiles range from poorest (quintile 1) to 
richest households (quintile 5). DS-TB=drug-sensitive tuberculosis. 
MDR-TB=multidrug-resistant tuberculosis.
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architecture of health systems, that can improve care-
seeking behaviour and health. The multifaceted benefits 
of tuberculosis interventions within the context of 
broader social development are intrinsically important to 
reductions in illness-related impoverishment.10,48,49
Our study builds on the substantial work of the 
TB Targets exercise,2,8 including the use of two dynamic 
models of tuberculosis transmission.35,36 Yet, our analysis 
had several limitations. First, we relied on modelled 
estimates of tuberculosis incidence and cost inputs2,8,35,36 
and on distributional assumptions. The lack of empirical 
evidence in these inputs points to the need for expanded 
data collection. Gathering information on tuberculosis-
related costs and time losses for patients and caregivers 
will be very important. Tracking out-of-pocket expenditure 
and related catastrophic costs over time could enable 
testing of the effects of policies in terms of poverty 
reduction with the existing research platforms of 
randomised controlled trials or household surveys.
Second, our estimation of tuberculosis-related house-
hold catastrophic costs was rudimentary. For example, we 
did not consider which member of the household was 
affected (eg, if the main earner had tuberculosis rather 
than other members of the household, catastrophic costs 
might have been more likely) because age-stratified 
tuberculosis incidence was not available from the model 
outputs. However, how tuberculosis-related income losses 
by age could be differentiated without adding unnecessary 
complications and assumptions in the absence of empirical 
information is unclear. We applied the simplifying 
assumption of one tuberculosis case per household, 
whereas the number of cases might be concentrated in 
specific households, such as those of the poorest and most 
marginalised populations. Additionally, variation in 
indirect costs with income has a consequence on public 
policy valuation (ie, by placing a higher value on time 
losses among the higher income quintiles than those in 
the lower quintiles). These effects might make 
interventions that benefit people in the top quintiles seem 
to be most cost-effective, which would have implications 
for equitable access to care. Other elements the models 
might have included were financial implications related to 
death (eg, long-term income losses), multiple medical cost 
inputs (eg, because richer individuals often seek private 
care), discounting and income growth over time, and the 
presence of social-protection programmes (eg, paid sick 
leaves). These adjustments, though, might have led to 
unnecessary complexity in the findings without providing 
any additional insight. 
Third, we represented financial protection in terms of 
cases of catastrophic costs averted. Other possible 
measures could have been cases of poverty or forced 
borrowing avoided. We chose household catastrophic 
costs averted because of its simplicity and widespread 
use,44,50 but this approach has some drawbacks, such as 
exclusion of some individuals through the choice of 
threshold (eg 20% of total income).44 We used the 
sensitivity analyses to try to lessen this effect.
Fourth, while the use of two models was a strength of 
this study because it allowed us to consider some 
uncertainty in the model structure, full characterisation 
of uncertainty in estimates was not possible and, 
therefore, our findings should be interpreted with 
caution. Owing to the many unknowns in the intervention 
scenarios we assessed, we used univariate sensitivity 
analyses and scenario analyses to assess the effects of key 
factors, and did a probabilistic sensitivity analysis to 
determine the 95% uncertainty ranges.
Irrespective of potential limitations, we believe this 
study has some robust and important findings. First, 
substantial financial household burden is incurred 
because of tuberculosis in India and South Africa, with 
millions of households being affected. Second, improved 
tuberculosis control through implementation or expan-
sion of selected services, such as those included in our 
models, could alleviate a notable proportion of that burden 
and disproportionately benefit the poorest house holds. 
Tuberculosis control alone, though, while necessary, will 
Figure 4: Number of households in South Africa per year with catastrophic 
costs averted by improved tuberculosis care and expanded access to care in 
2016–35
(A) Harvard model. (B) TB Impact Model and Estimates model. 
DS-TB=drug-sensitive tuberculosis. MDR-TB=multidrug-resistant tuberculosis.
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not be sufficient to achieve the End TB Strategy targets 
because the indirect costs are high. Other social-protection 
strategies and safety nets actions will be needed to 
substantially reduce catastrophic costs. In this respect, 
future work should estimate the additional financial 
resources needed to eliminate catastrophic costs by 2030, 
and assess whether governments should  cover the full 
social cost of tuberculosis treatment for at-risk households 
in India and South Africa. This study has illustrated what 
financial protection might be achieved with various 
scenarios, but, importantly, our analysis remains only a 
stepping stone towards the essential process of involving 
policy makers and academics, who must make their own 
assessments of model assumptions so that our findings 
can best inform the policy dialogues in India and South 
Africa, particularly regarding feasibility, affordability, and 
value for money, and reflect the true scenarios of 
tuberculosis control in the two countries.
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